G1 Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for COSELA™ (Trilaciclib) in Combination with Chemotherapy for the Treatment of Locally Advanced or Metastatic Triple Negative Breast Cancer

Daniel Sontupe
Market Access

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Matt Turner
Patient Affordability

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Pat Purcell
Meeting Engagement

Joey Cohen
Medication Adherence

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition